H Ring-Larsen
Overview
Explore the profile of H Ring-Larsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
850
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mangia A, Dalgard O, Minerva N, Verbaan H, Bacca D, Ring-Larsen H, et al.
Aliment Pharmacol Ther
. 2010 Mar;
31(12):1346-53.
PMID: 20222909
Background: The optimal dose of ribavirin to be used in combination with Peg-IFN in patients with HCV genotypes 2 and 3 undergoing short treatment has not been established. Aim: To...
2.
Schmidt L, Ring-Larsen H
Curr Pharm Des
. 2006 Dec;
12(35):4637-47.
PMID: 17168767
Hepatorenal syndrome is a severe, but not uncommon complication of decompensated liver cirrhosis. In particular, the rapidly progressive form of hepatorenal syndrome (type 1) is associated with a dismal prognosis....
3.
Gronbaek K, Bygum Krarup H, Ring-Larsen H, Schaffalitzky de Muckadell O, Moller A, Schlichting P, et al.
Scand J Gastroenterol
. 2002 Aug;
37(7):840-4.
PMID: 12190100
Background: To compare the effect of combination therapy with interferon-alpha (INF-alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to monotherapy with INF-alpha in patients with chronic hepatitis C infection. Methods: Forty-five consecutive...
4.
5.
Henriksen J, Siemssen O, Krintel J, Malchow-Moller A, Bendtsen F, Ring-Larsen H
J Hepatol
. 2001 Feb;
34(1):53-60.
PMID: 11211908
Background/aims: To determine dynamics of albumin in plasma and ascitic fluid of patients with cirrhosis. Methods: Forty-seven patients were classified in four groups: I--patients without fluid retention; II--patients with ascites...
6.
Gronbaek K, Krarup H, Moller H, Krogsgaard K, Franzmann M, Sonne J, et al.
J Hepatol
. 1999 Dec;
31(5):800-7.
PMID: 10580576
Background/aims: Consecutive patients originally diagnosed with acute non-A, non-B hepatitis were followed up to assess the long-term morbidity and mortality and to re-evaluate the etiology in surviving patients. Methods: Follow-up...
7.
Janssen H, Gerken G, Carreno V, Marcellin P, Naoumov N, Craxi A, et al.
Hepatology
. 1999 Jul;
30(1):238-43.
PMID: 10385662
Interferon alfa (IFN-alpha) is the primary treatment for chronic hepatitis B. The standard duration of IFN-alpha therapy is considered 16 weeks; however, the optimal treatment length is still poorly defined....
8.
Krogsgaard K, Marcellin P, Trepo C, Berthelot P, Sanchez-Tapias J, Bassendine M, et al.
Ugeskr Laeger
. 1998 Oct;
160(39):5657-61.
PMID: 9771059
Patients (n = 213) with chronic hepatitis B were randomised to prednisolone (two weeks of 0.6 mg/kg/day, one week of 0.45 mg/kg/day and one week of 0.25 mg/kg/day) or placebo...
9.
Henriksen J, Moller S, Ring-Larsen H, Christensen N
J Hepatol
. 1998 Aug;
29(2):328-41.
PMID: 9722218
No abstract available.
10.
Joffe P, Larsen F, Pedersen V, Ring-Larsen H, Sidhu J
Eur J Clin Pharmacol
. 1998 Jul;
54(3):237-42.
PMID: 9681666
Objective: To compare the pharmacokinetics of the antidepressant citalopram and its metabolites demethylcitalopram and didemethylcitalopram in subjects with moderate renal insufficiency and subjects with hepatic cirrhosis with that in healthy...